Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
about
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanomaCTLA-4 blockade: therapeutic potential in cancer treatmentsRegulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingTelomere and Telomerase Therapeutics in CancerCo-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Suppression, subversion and escape: the role of regulatory T cells in cancer progressionThe role of immune checkpoint inhibition in the treatment of ovarian cancerImmune checkpoint blockade: a common denominator approach to cancer therapyModification of the tumor microenvironment as a novel target of renal cell carcinoma therapeuticsAdministration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.Immunotherapy: Vaccine trials in melanoma -- time for reflection.Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyCTLA4 blockade broadens the peripheral T-cell receptor repertoireTargeting the PD-1 pathway: a promising future for the treatment of melanoma.Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalCTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cellsReleasing the brake on the immune system: ipilimumab in melanoma and other tumorsMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.New Immunotherapy Strategies in Breast Cancer.Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitOptimizing dendritic cell-based approaches for cancer immunotherapyAssociation of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologicallyInhibitory costimulation and anti-tumor immunity.Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administrationDiffering patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Biomarkers on melanoma patient T cells associated with ipilimumab treatment.Checkpoint blockade in cancer immunotherapyTherapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.CD4 regulatory T cells in human cancer pathogenesis.
P2860
Q24618690-6B7A5373-A49B-487D-A8D4-0C429C4BDA10Q24622666-BA26F2C3-96B1-4D58-83A4-13AE775F449FQ26742012-CD248B00-7B09-465B-9AC5-AE3C42CA1D45Q26744808-2FD99934-FD52-488B-AD06-64FD0DAB6BFEQ26796099-A9F49A61-4C14-435E-B376-AC98B1DD2591Q27026151-E8A3F75C-AB56-4AAA-83DB-63704AECF6D4Q28077924-CBE5F053-97E2-4C61-A5AD-46202EA36F2AQ28083981-A3F360FC-5D9E-4AF7-B64C-358156548D7BQ28393614-F984A752-6275-4480-9578-6BC66DFC0A71Q33299427-581264E2-AC4C-4DE0-9A73-75CAC7C0C387Q33434380-20B54A7A-585D-43B4-B829-79E17C3708C4Q33522281-973168ED-3A58-4A57-8405-A40F66A53C63Q33560753-BCEE7932-C07A-408F-91A8-B96768BD77DDQ33946513-FA37B788-89F9-48F7-8C05-5C9575070ECCQ34048270-DB99B92C-3098-4731-B38B-DDC20E686311Q34355686-FC1C43EA-7824-4A06-97F7-A69A25124607Q34447732-ABA2576C-2A2F-4BB7-A5CE-C9F67FAD66D6Q34522172-2AB24DB3-AFE2-455A-BD84-B26AD1394B4DQ34549227-3C90935A-CA2D-4BAE-A29D-4FA4417D101CQ34567635-C0C37F98-8EBC-420E-BD41-1073B9659C33Q34588220-C3FF275F-0F69-4F23-B2F4-59F6B82FC845Q34601772-B4125D36-C130-48F8-8675-EDEBD8702ECFQ34637535-9D4A2AA9-B883-45BE-83A6-988922D268DDQ34651347-F18E8891-A41C-4945-9567-DC78AE23E27DQ34720087-F95208D5-B0C6-4043-B653-65123101A5F2Q35053486-A68C0A99-C446-4192-84CF-D6F252DD2526Q35058213-025B5C50-0201-4156-B019-1EC3DBF2088FQ35101747-6BA9B3C6-28CF-4CF2-89F1-2F718FAD1580Q35328438-5DC33639-092F-4328-9E37-853F5726975BQ35928288-965A4CCF-94CC-416C-BCB6-29AB0616C389Q36016292-B9663E54-9F44-43CE-8A54-6EB382AF2B8BQ36106006-59107291-2BB4-4479-AD90-39F4F69DFD5DQ36286133-CDFC8A4D-380A-4AC2-A96F-93A06509E2C2Q36293343-666F4398-D5F1-4925-8977-07606E59ABDAQ36344582-CB5B94B8-3B5D-4A57-8309-8E000673EF30Q36443331-C3D5A496-4A89-4D84-9871-B53C3FA1BA21Q36480617-3AE30DFE-BCF3-4894-829C-8C70D7E7D690Q36490768-75842D58-B1C1-4BA7-BAC2-C9314A78C12EQ36499222-AF5304CD-E563-4F16-8A59-49C0D712E984Q36526954-C9CBA0B3-3DFA-432B-85EF-93E3B0E9B2EE
P2860
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@ast
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@en
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@nl
type
label
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@ast
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@en
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@nl
prefLabel
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@ast
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@en
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@nl
P2093
P2860
P1476
Analysis of the cellular mecha ...... treated with CTLA-4 blockade.
@en
P2093
Ajay V Maker
Peter Attia
Steven A Rosenberg
P2860
P304
P356
10.4049/JIMMUNOL.175.11.7746
P407
P577
2005-12-01T00:00:00Z